Cell freezing medium for clinical use
US11363812B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 25, 2017 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Jul 29, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2500/62
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) cryoprotectant: the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol, and ethylene glycol; (3) a saline buffer; wherein the salt buffer is a solution containing Na+, K+, Mg+, Cl−, and CH3COO− ions; (4) a vitamin; and (5) an amino acid, wherein the human albumin concentration is 1%-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used or conventional adherent and suspension cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.